Cerus
CERS | NASDAQ
$1.86
-$0.13 (-6.30%)
At close: Nov 16, 2026, 4:00 PM ET
$1.86
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Cerus Company Profile
Company profile explainedCompany Profile
Cerus Corporation operates as a biotechnology firm dedicated to advancing and marketing the INTERCEPT Blood System. This proprietary technology significantly enhances the safety of transfusable blood components by neutralizing biological threats, thereby reducing the risk of blood-borne pathogens. The company's product line includes INTERCEPT systems specifically engineered to deactivate pathogens in donated platelets and plasma. It also offers a dedicated INTERCEPT Blood System for the inactivation of harmful agents in red blood cell components. Furthermore, Cerus markets an INTERCEPT Blood System for Cryoprecipitation, which leverages its plasma technology to produce two key pathogen-reduced blood products: a cryoprecipitated fibrinogen complex for treating and controlling bleeding, particularly massive hemorrhages stemming from fibrinogen deficiency, and pathogen-reduced, cryoprecipitate-reduced plasma. Cerus distributes these platelet and plasma systems globally through a combination of its direct sales force and an extensive network of distributors, reaching markets in North America, Europe, the Commonwealth of Independent States, the Middle East, and Latin America. Established in 1991, Cerus Corporation maintains its corporate headquarters in Concord, California.
Key Executives
| Name | Position |
|---|---|
| Vivek K. Jayaraman | President, Chief Executive Officer & Director |
| Chrystal Jensen | Chief Legal Officer, General Counsel & Secretary |
| Kevin D. Green | Vice President of Finance & Chief Financial Officer |
| Bianca Vos | Vice President of Administration |
| Christian Boutemy | VP & MD of Cerus International |
| Lainie Corten | Vice President of Global Marketing |
| Nina Mufti | Senior Vice President of Research & Development |
| Richard J. Benjamin | Chief Medical Officer |
| Timothy J. Lee | Head of Investor Relation |
| William Greenman | Executive Chairman of the Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 17, 2026 | 4 | Filing |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 13, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Jul 30, 2026 | S-8 | Filing |
| Jul 30, 2026 | 10-Q | Quarterly Report |
| Jul 30, 2026 | 8-K | Current Report |
| Jul 20, 2026 | 4 | Filing |
| Jul 10, 2026 | 8-K | Current Report |
| Jul 02, 2026 | 4 | Filing |
Cerus
| Country | United States |
| IPO Date | Jan 31, 1997 |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Employees | 268 |
| CEO | Vivek K. Jayaraman |
Contact Details
1220 Concord Avenue Concord,
California 94520 United States
Stock Details
| Ticker Symbol | CERS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001020214 |
| CUSIP Number | 157085101 |
| ISIN Number | US1570851014 |
| SIC Code | 3841 |
Add to Watchlist
Select watchlists to add or remove CERS